The same drug target, pursued for benefit: menin inhibition is a diabetes strategy in the literature
also called menin inhibitor diabetes · beta cell regeneration menin · the inversion
This project treats blocking menin as a risk to hormone glands. But a separate group of scientists has been trying to block menin on purpose, as a treatment for diabetes, because it makes insulin-producing cells multiply. Both literatures are about the same drug in the same tissue.
The same thing, for a scientist
A map entry, written because the `endocrine/` beat framed normal-tissue menin almost entirely as a toxicity risk and contained no entry for the literature running the other way. Menin inhibition has been pursued as a beta-cell regeneration strategy for diabetes across at least eight primary papers spanning 2007-2025, in mouse genetics, rat and human islets, enteroendocrine cells and diet-induced diabetic mice [E1][E2][E3][E4][E5]. The strongest single result is that a menin inhibitor given daily for 12 weeks lowered fasting glucose and raised beta-cell mass in diabetic mice [E3]. **This is not a rebuttal of the toxicity case.** It is the same intervention in the same tissue read at a different duration and with a different endpoint, and the graph should hold both.
The programme, in order
| Year | Finding | Entry |
|---|---|---|
| 2007 | Menin falls in pregnancy to permit beta-cell expansion; forcing it high causes gestational diabetes | mechanism-menin-is-a-reversible-physiological-brake-on-beta-cells |
| 2010 | Acute Men1 excision reverses established hyperglycaemia in three diabetic models | mechanism-acute-men1-deletion-reverses-established-hyperglycaemia |
| 2012 | Glucose itself represses menin via PI3K/Akt/Foxo1 to permit proliferation | mechanism-menin-is-a-reversible-physiological-brake-on-beta-cells |
| 2014 | Menin blocks the RAF/MAPK arm of K-RAS; GLP1 agonist plus menin inhibitor synergise | mechanism-menin-blocks-kras-to-mapk-output-in-endocrine-cells |
| 2017 | Menin and PRMT5 repress GLP1R; menin inhibition raises Ki67 in mouse and human islets | mechanism-menin-prmt5-represses-glp1r-transcription |
| 2020-21 | MI-2 plus TGF-beta inhibition replicates adult human beta cells without losing insulin production | mechanism-menin-inhibition-replicates-human-beta-cells-ex-vivo |
| 2021 | MI-463 70 mg/kg/day for 12 weeks: fasting glucose down, beta-cell mass up, Pbk-dependent | mechanism-in-vivo-islet-phenotype-under-pharmacological-menin-inhibition |
| 2023 | MENIN is a TEAD1 corepressor in beta cells; proposed as a target to augment proliferation | mechanism-menin-is-a-tead1-corepressor-in-beta-cells |
| 2025 | MI-463 raises gut GLP-1 via beta-catenin/TCF7L2 and improves glucose tolerance | mechanism-menin-inhibition-raises-gut-glp1-secretion |
How to hold both without collapsing into either
The two literatures are not in contradiction; they are measuring different things about one pharmacology.
- They agree on the direction: menin restrains endocrine cell proliferation and menin inhibition releases it.
- They differ on duration: the diabetes literature studies weeks to three months; the toxicity literature studies decades of germline loss and a regulator asking about three years of drug.
- They differ on tissue: the benefit is demonstrated in the islet and the gut; the human drug signal is in the parathyroid and the mineral axis, where the benefit literature has nothing at all - not one paper has put a menin inhibitor on a parathyroid cell.
- They differ on endpoint: glucose tolerance and beta-cell mass versus PTH, phosphate, growth plate and tumour.
The defensible synthesis is therefore tissue-divergent and duration-dependent, not "menin inhibition is safe" and not "menin inhibition is dangerous". That synthesis is stated as a testable claim in hyp-menin-inhibition-is-tissue-divergent.
What is genuinely better supported on each side
Better supported on the benefit side: that menin restrains beta-cell proliferation (multiple models, bidirectional manipulation, human tissue); that menin represses GLP1R; that pharmacological menin inhibition improves glucose handling in diabetic mice over 8-12 weeks.
Better supported on the harm side: that menin loss in the parathyroid causes neoplasia and hypercalcaemia cell-autonomously; that osteoblast/osteocyte menin loss lowers bone mass, bidirectionally; that both approved compounds are skeletal teratogens below clinical exposure; that revumenib closes growth plates irreversibly in juvenile rats; that intact PTH rises in 34% of treated patients.
Supported on neither side: anything at all about what a clinical menin inhibitor does to a child's glucose, insulin, bone density, height velocity, puberty or parathyroid, because none of it is measured.
| primary papers | 9 |
|---|---|
| clinical compounds used | none |
| parathyroid papers in this literature | 0 |
span years
[ 2007, 2025 ]
tissues
[ "mouse islet", "rat islet", "human donor islet", "human MEN1 iPSC beta-like cells", "intestinal enteroendocrine" ]
- The existence of a benefit literature is not protection: it studies a different tissue, a different duration and a different endpoint from the one that matters for a child.
- Every paper in the benefit literature uses tool compounds; if the clinical molecules engage the endocrine axis more weakly, the benefit disappears while the leukaemia-directed risks do not.
- Presenting the inversion as reassurance would be the same error the beat made in the other direction, and would make the graph wrong twice.
- Has any pharmaceutical company taken a menin inhibitor into a diabetes trial? No such trial appears in the literature reviewed here, and the reason may itself be informative.
- Why has this literature never measured the parathyroid, when it uses systemic dosing in whole animals for 12 weeks?
- Could a paediatric leukaemia programme and a diabetes programme share a single endocrine safety dataset?
- E1strong confidence 4 of 5: Replicated in peer-reviewed work by more than one group.paper
Menin restrains beta-cell proliferation physiologically and its forced expression causes gestational diabetes in mice.
Menin controls growth of pancreatic beta-cells in pregnant mice and promotes gestational diabetes mellitus. · Karnik SK, Chen H, McLean GW, Heit JJ, Gu X, Zhang AY, et al. · Science 2007What this evidence cannot show
Mouse pregnancy model.
Evidence that argues against this (1)
- The same restraint, permanently removed, is the mechanism of MEN1 insulinoma. Harding B et al. 2009
- E2strong confidence 4 of 5: Replicated in peer-reviewed work by more than one group.paper
Acute Men1 excision reverses pre-existing hyperglycaemia in streptozotocin, db/db and high-fat-diet mice.
Reversal of preexisting hyperglycemia in diabetic mice by acute deletion of the Men1 gene. · Yang Y, Gurung B, Wu T, Wang H, Stoffers DA, Hua X · Proceedings of the National Academy of Sciences USA 2010What this evidence cannot show
Genetic, not pharmacological; no tumour follow-up.
Evidence that argues against this (1)
- Longer follow-up of the same manipulation gives glucagon-expressing tumours and beta-cell identity loss. Li F et al. 2015
- E3moderate confidence 3 of 5: One strong study, or several smaller consistent ones.paper
A menin inhibitor given daily for 12 weeks lowered fasting glucose and increased beta-cell mass in diabetic mice.
Menin-regulated Pbk controls high fat diet-induced compensatory beta cell proliferation. · Ma J, Xing B, Cao Y, He X, et al. · EMBO Molecular Medicine 2021What this evidence cannot show
Tool compound MI-463, n=4-5, no neoplasia assessment, no off-drug arm.
Evidence that argues against this (1)
- Revumenib's own toxicology reports irreversible pancreatic hyperplasia in rats at ~2x human AUC - the same organ, graded as toxicity. Syndax Pharmaceuticals et al. 2026
- E4moderate confidence 3 of 5: One strong study, or several smaller consistent ones.paper
A menin inhibitor raises Ki67 in mouse and human pancreatic islets ex vivo and de-represses GLP1R.
Menin and PRMT5 suppress GLP1 receptor transcript and PKA-mediated phosphorylation of FOXO1 and CREB. · Muhammad AB, Xing B, Liu C, Naji A, et al. · American Journal of Physiology - Endocrinology and Metabolism 2017What this evidence cannot show
Ex vivo, tool compound, concentrations not stated in the abstract.
Evidence that argues against this (1)
- GLP-1R up-regulation is also the imaging signature of pre-neoplastic Men1 islets. Monazzam A et al. 2018
- E5moderate confidence 3 of 5: One strong study, or several smaller consistent ones.paper
A menin-MLL inhibitor synergises with TGF-beta inhibition to replicate adult human beta cells without loss of insulin production.
Combined inhibition of menin-MLL interaction and TGF-beta signaling induces replication of human pancreatic beta cells. · Pahlavanneshan S, Behmanesh M, Oropeza D, Furuyama K, Tahamtani Y, Basiri M, et al. · European Journal of Cell Biology 2020What this evidence cannot show
Ex vivo human donor islets; requires a second drug; MI-2 is a low-potency early tool compound.
Evidence that argues against this (1)
- The effect runs through down-regulation of p21, p27 and p18 - the same restraint whose loss drives Men1 neuroendocrine tumours. Harding B et al. 2009
The strongest single result in the benefit literature: 12 weeks of MI-463 lowers fasting glucose and raises beta-cell mass
The GLP1R arm, and the source of the human-islet Ki67 result
- refutes →The same pocket suppresses JUND: menin inhibition's unmeasured endocrine liability in infants
That entry frames every normal-tissue consequence of pocket occupancy as an unmeasured liability; a nine-paper literature spanning 2007-2025 pursues the same occupancy in the same tissue for benefit, and the entry does not mention it
The two literatures are reconciled only by exposure class and tissue, not by one of them being wrong
The one endpoint the benefit literature predicts would move is the one endpoint neither label reports; a glucose row would be decisive in either direction and costs nothing